Genetic deletion of mPGES-1 accelerates intestinal tumorigenesis in APCMin/+ mice

Biochemical and Biophysical Research Communications

Volumn 372, Issue 1, 2008, Pages 249-253

  Elander, N ^a   Ungerback J ^a   Olsson, H ^b   Uematsu, S ^c   Akira, S ^c   Soderkvist P ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

APCMin + mouse; Colorectal cancer; Microsomal prostaglandin E synthase 1 (mPGES 1); Prostaglandin E2 (PGE2)

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; LIPID; PROSTAGLANDIN D2; PROSTAGLANDIN E SYNTHASE; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E SYNTHASE 2; PROSTAGLANDIN E2; PROSTAGLANDIN H2; PROSTANOID; THROMBOXANE A2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CANCER THERAPY; CARCINOGENESIS; CATALYSIS; COLORECTAL CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; GENE DELETION; INTESTINE TUMOR; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SYNTHESIS; WILD TYPE;

6-KETOPROSTAGLANDIN F1 ALPHA; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; DINOPROSTONE; FEMALE; GENE DELETION; INTRAMOLECULAR OXIDOREDUCTASES; MALE; MICE; MICE, MUTANT STRAINS; RNA, MESSENGER; THROMBOXANE B2;

ANIMALIA; MUS;

EID: 44649137303     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.05.026     Document Type: Article

References (27)

1. Chell S., Kaidi A., Williams A.C., and Paraskeva C. Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochim. Biophys. Acta 1766 (2006) 104-119
2. Pradono P., Tazawa R., Maemondo M., Tanaka M., Usui K., Saijo Y., Hagiwara K., and Nukiwa T. Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res. 62 (2002) 63-66
3. Sakai H., Suzuki T., Takahashi Y., Ukai M., Tauchi K., Fujii T., Horikawa N., Minamimura T., Tabuchi Y., Morii M., Tsukada K., and Takeguchi N. Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2. FEBS Lett. 580 (2006) 3368-3374
4. Yokoyama I., Hayashi S., Kobayashi T., Negita M., Yasutomi M., Uchida K., and Takagi H. Prevention of experimental hepatic metastasis with thromboxane synthase inhibitor. Res. Exp. Med. (Berl) 195 (1995) 209-215
5. Qualtrough D., Kaidi A., Chell S., Jabbour H.N., Williams A.C., and Paraskeva C. Prostaglandin F(2alpha) stimulates motility and invasion in colorectal tumor cells. Int. J. Cancer 121 (2007) 734-740
6. Gupta R.A., Tan J., Krause W.F., Geraci M.W., Willson T.M., Dey S.K., and DuBois R.N. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc. Natl. Acad. Sci. USA 97 (2000) 13275-13280
7. Cutler N.S., Graves-Deal R., LaFleur B.J., Gao Z., Boman B.M., Whitehead R.H., Terry E., Morrow J.D., and Coffey R.J. Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells. Cancer Res. 63 (2003) 1748-1751
8. Wang D., Wang H., Guo Y., Ning W., Katkuri S., Wahli W., Desvergne B., Dey S.K., and DuBois R.N. Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proc. Natl. Acad. Sci. USA 103 (2006) 19069-19074
9. Mutoh M., Watanabe K., Kitamura T., Shoji Y., Takahashi M., Kawamori T., Tani K., Kobayashi M., Maruyama T., Kobayashi K., Ohuchida S., Sugimoto Y., Narumiya S., Sugimura T., and Wakabayashi K. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res. 62 (2002) 28-32
10. Zamuner S.R., Bak A.W., Devchand P.R., and Wallace J.L. Predisposition to colorectal cancer in rats with resolved colitis: role of cyclooxygenase-2-derived prostaglandin d2. Am. J. Pathol. 167 (2005) 1293-1300
11. Yoshimatsu K., Golijanin D., Paty P.B., Soslow R.A., Jakobsson P.J., DeLellis R.A., Subbaramaiah K., and Dannenberg A.J. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin. Cancer Res. 7 (2001) 3971-3976
12. Kamei D., Murakami M., Nakatani Y., Ishikawa Y., Ishii T., and Kudo I. Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J. Biol. Chem. 278 (2003) 19396-19405
13. Uematsu S., Matsumoto M., Takeda K., and Akira S. Lipopolysaccharide-dependent prostaglandin E(2) production is regulated by the glutathione-dependent prostaglandin E(2) synthase gene induced by the Toll-like receptor 4/MyD88/NF-IL6 pathway. J. Immunol. 168 (2002) 5811-5816
14. Shoemaker A.R., Gould K.A., Luongo C., Moser A.R., and Dove W.F. Studies of neoplasia in the Min mouse. Biochim. Biophys. Acta 1332 (1997) F25-F48
15. Hull M.A., Ko S.C., and Hawcroft G. Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer?. Mol. Cancer Ther. 3 (2004) 1031-1039
16. Pugh S., and Thomas G.A. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut 35 (1994) 675-678
17. Rigas B., Goldman I.S., and Levine L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. 122 (1993) 518-523
18. Murakami M., and Kudo I. Prostaglandin E synthase: a novel drug target for inflammation and cancer. Curr. Pharm. Des. 12 (2006) 943-954
19. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., Trzaskos J.M., Evans J.F., and Taketo M.M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87 (1996) 803-809
20. Barnes C.J., and Lee M. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology 114 (1998) 873-877
21. Jacoby R.F., Seibert K., Cole C.E., Kelloff G., and Lubet R.A. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. 60 (2000) 5040-5044
22. Oshima M., Murai N., Kargman S., Arguello M., Luk P., Kwong E., Taketo M.M., and Evans J.F. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. 61 (2001) 1733-1740
23. Boulet L., Ouellet M., Bateman K.P., Ethier D., Percival M.D., Riendeau D., Mancini J.A., and Methot N. Deletion of microsomal prostaglandin E2 (PGE2) synthase-1 reduces inducible and basal PGE2 production and alters the gastric prostanoid profile. J. Biol. Chem. 279 (2004) 23229-23237
24. Brenneis C., Coste O., Schmidt R., Angioni C., Popp L., Nusing R.M., Becker W., Scholich K., and Geisslinger G. Consequences of altered eicosanoid patterns for nociceptive processing in mPGES-1-deficient mice. J. Cell. Mol. Med. 12 (2008) 639-648
25. Trebino C.E., Eskra J.D., Wachtmann T.S., Perez J.R., Carty T.J., and Audoly L.P. Redirection of eicosanoid metabolism in mPGES-1-deficient macrophages. J. Biol. Chem. 280 (2005) 16579-16585
26. Park J.M., Kanaoka Y., Eguchi N., Aritake K., Grujic S., Materi A.M., Buslon V.S., Tippin B.L., Kwong A.M., Salido E., French S.W., Urade Y., and Lin H.J. Hematopoietic prostaglandin D synthase suppresses intestinal adenomas in ApcMin/+ mice. Cancer Res. 67 (2007) 881-889
27. Wang D., and Dubois R.N. Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett. (2008)